The strongest evidence can be found in a database kept by the National Institutes of Health (NIH) and the National Center for Biotechnology Information (NCBI). Known as BLAST, the database catalogs all known gene sequences found in nature, along with all synthetic gene sequences that have been patented.
Researchers decided to check BLAST for the RNA sequence of the furin cleavage sequence found in the SARS-CoV-2 spike protein to see if it could be found anywhere else in nature. It is the only continuous nucleotide sequence in COVID-19 that has more than three nucleotides that differ from their respective letters in the virus’s closest natural relative, the Bat Coronavirus RaTG13. This cleavage site is also the key to COVID-19's pathogenicity, making it the most likely place for a manmade gain of function to be found in the virus. The structure has been one of the focuses of the debate about the origins of the virus as some scientists have long insisted that it could not have been acquired naturally.
The researchers found five U.S. patents that contained the same nucleotide sequence, and the earliest one had been applied for by Moderna back in December 2013. Furthermore, it does not exist in nature at all. The other subsequent patents were also filed by Moderna in the years that followed.
This demonstrates that the vaccine maker actually developed the 19-nucleotide gene sequence that contains the furin cleavage site responsible for making the virus so infectious in humans. If this genetic tampering had not occurred, the original coronaviruses that COVID-19 was engineered from would have only infected animals.
Researchers have said that the likelihood of a match they found to a patent filed by Moderna on February 4, 2016, developing naturally on its own is 1 in 3 trillion. It would appear, therefore, that the company was already in a position to capitalize on this virus long before the pandemic got underway.
Adding fuel to the fire is the fact that Moderna started making its COVID-19 vaccine weeks before the first official outbreak was reported. Their vaccine was already in development as early as December 2019, which was at least two weeks before the confirmation of the outbreak came from China.
Of course, we also know that the Wuhan Institute of Virology had been carrying out gain-of-function research in bat coronavirus samples as far back as 2015 with funding from Dr. Anthony Fauci. The Fauci-led National Institute of Allergy and Infectious Diseases (NIAID) started a partnership with Moderna to develop an mRNA vaccine against the coronaviruses studied at the lab right around that same time.
It is interesting to note, of course, that nature has never created a virus with that sequence, yet six years after Moderna referred to it in their patents, it has been found in a virus for which the company has created a vaccine. Now, they have raked in billions of dollars from their jab, which is the vaccine maker’s only marketed product and one of just three vaccines to have been approved for use in the U.S.
For 2021 alone, Moderna earned $12.2 billion in a strong reversal of fortune from 2020, when they recorded a net loss of $747 million. Analysts have forecasted Moderna’s 2022 vaccine sales to reach $20.74 billion as boosters continue to be pushed on the masses.
Sources for this article include: